TD-1792 versus vancomycin for treatment of complicated skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 11, 2012, Pages 5476-5483

  Stryjewski, Martin E ^a,b   Potgieter, Peter D ^c   Li, Yu Ping ^c   Barriere, Steven L ^c   Churukian, Allan ^d   Kingsley, Jeff ^e   Corey, G Ralph ^b,f  

^a CEMIC   (Argentina)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c THERAVANCE INC   (United States)

^d SHARP HEALTHCARE   (United States)

^e SERRG Inc   (United States)

^f DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM; CEPHALOSPORIN DERIVATIVE; CHLORIDE; CREATININE; NITROGEN; POLYPEPTIDE ANTIBIOTIC AGENT; POTASSIUM; TD 1792; UNCLASSIFIED DRUG; UREA; VANCOMYCIN;

ABDOMINAL PAIN; ABSCESS; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL SKIN DISEASE; BLOOD CULTURE; BLOOD PRESSURE; CALCIUM BLOOD LEVEL; CELLULITIS; CHLORIDE BLOOD LEVEL; CONSTIPATION; CONTROLLED STUDY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; ENTEROCOCCAL INFECTION; ENTEROCOCCUS; ERADICATION THERAPY; FATIGUE; FEMALE; FOLLOW UP; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HEART PALPITATION; HEART RATE; HUMAN; HYPOGLYCEMIA; IN VITRO STUDY; INFUSION RELATED REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INSOMNIA; LIMB ABSCESS; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RED MAN SYNDROME; SIDE EFFECT; SKIN ABSCESS; SKIN ALLERGY; SKIN STRUCTURE; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS INTERMEDIUS; STREPTOCOCCUS MITIS; STREPTOCOCCUS PYOGENES; TREATMENT DURATION; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLYCOPEPTIDES; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; SKIN; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84868023726     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00712-12     Document Type: Article

References (27)

1. Agresti A, Caffo B. 2007. Simple and effective confidence intervals for proportions and difference of proportions result from adding two successes and two failures. Am. Statistician 54:280-288.
2. Bae IG, et al. 2009. Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. J. Infect. Dis. 200: 1355-1366.
3. Blais J, Li YP, Barriere S. 2009. Activity of Td-1792, a multivalent glyco-peptide-cephalosporin antibiotic, against Gram-positive isolates from a recently completed phase 2 study in complicated skin and skin structure infection, abstr. E-209. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
4. Boucher HW, Corey GR. 2008. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S344-S349.
5. Burton DC, Edwards JR, Horan TC, Jernigan JA, Fridkin SK. 2009. Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007. JAMA 301: 727-736.
6. Difuntorum S, et al. 2007. In vitro and in vivo evidence for a multivalent mode of action of Td-1792 against Staphylococcus aureus, abstr. F1-2110. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
7. Fritsche TR, Blais J, Jones RN. 2007. In vitro evaluation of Td-1792, a novel antimicrobic with potent Gram-positive activity, abstr. E-1627. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
8. Gonzalez BE, et al. 2006. Community-associated strains of methicillin-resistant Staphylococccus aureus as the cause of healthcare-associated infection. Infect. Control Hosp. Epidemiol. 27:1051-1056.
9. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. 2006. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet 368:874-885.
10. Hedge SS, et al. 2007. Efficacy of Td-1792, a novel multivalent glycopeptide, against Gram-positive pathogens in the neutropenic thigh model, abstr. A-42. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
11. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. 2006. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch. Intern. Med. 166:2138-2144.
12. King MD, et al. 2006. Emergence of community-acquired methicillin-resistant Staphylococcus aureus U. S. A. 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144:309-317.
13. Klevens RM, et al. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
14. Lee MC, et al. 2004. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr. Infect. Dis. J. 23:123-127.
15. Long DD, et al. 2008. Exploring the positional attachment of glycopeptide/beta-lactam heterodimers. J. Antibiot. (Tokyo) 61:603-614.
16. Lunde CS, Lewis SR, Benton BM, Mammen M, Blais J. 2009. Td-1792, mode of action of a multivalent glycopeptide-cephalosporin antibiotic, abstr. C1-1344. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA
17. Moran GJ, et al. 2006. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355:666-674.
18. Olshansky B, et al. 2008. Differential pharmacological effects of antimus-carinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J. Cardiovasc. Pharmacol. Ther. 13:241-251.
19. Rajendran PM, et al. 2007. Randomized, double-blind, placebo-controlled trial of cephalexin for treatment of uncomplicated skin abscesses in a population at risk for community-acquired methicillin-resistant Staphylococcus aureus infection. Antimicrob. Agents Chemother. 51:4044-4048.
20. Rosenthal VD, et al. 2008. International nosocomial infection control consortium report, data summary for 2002-2007, issued January 2008. Am. J. Infect. Control 36:627-637.
21. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment ofmethicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398-2402.
22. Seybold U, et al. 2006. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin. Infect. Dis. 42:647-656.
23. Shaw JP, et al. 2007. Pharmacokinetics of Td-1792, a novel multivalent glycopeptide, in preclinical animal species, abstr. A-43. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
24. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200.
25. Stryjewski ME, Chambers HF. 2008. Skin and soft-tissue infections caused by community-acquired methicillin-resistant Staphylococcus aureus. Clin. Infect. Dis. 46(Suppl 5):S368-S377.
26. US Food and Drug Administration. 2010. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. http://www.fda.gov/Downloads/Drugs/Guidancecomplianceregulatoryinformation/ Guidances/Ucm071185. Pdf. Accessed 30 March 2012.
27. Wong SL, et al. 2007. Pharmacokinetic (Pk) disposition of a novel multivalent glycopeptide, Td-1792, abstr. A-44. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.